Literature DB >> 21544066

Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy.

Frédéric-Antoine Dauchy1, Sylvie Lawson-Ayayi, Renaud de La Faille, Fabrice Bonnet, Claire Rigothier, Nadia Mehsen, Ghada Miremont-Salamé, Charles Cazanave, Carine Greib, Francois Dabis, Michel Dupon.   

Abstract

Abnormal kidney function is common in the course of human immunodeficiency virus (HIV) infection. Here, we performed a cross-sectional analysis using 399 patients within the Aquitaine cohort (a hospital-based cohort of HIV-1-infected patients receiving routine clinical management) to estimate the prevalence of proximal renal tubular dysfunction (PRTD) associated with HIV infection. These patients did not differ statistically by sociodemographics, median age, years since HIV diagnosis, AIDS stage, or median CD4 cell count from the entire 3080 patient cohort. Antiretroviral therapy was received by 352 patients, with 256 given tenofovir (TDF); 325 had undetectable HIV plasma viral load, and 26 were diagnosed with PRTD. In multivariate analysis, significant independent associations were found between PRTD and age (odds ratio (OR) 1.28 per 5-year increase), atazanavir (OR 1.28 per year of exposure), and TDF (OR 1.23 per year) treatment. Among patients having received TDF-containing regimens over a 5-year period, PRTD remained significantly associated with TDF exposure when treatment was ongoing (OR 5.22) or had been discontinued (OR 11.49). Thus, cumulative exposure to TDF and/or atazanavir was associated with an increased risk of PRTD, with concern about its reversibility in patients with HIV.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544066     DOI: 10.1038/ki.2011.124

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  50 in total

1.  Association of tenofovir exposure with kidney disease risk in HIV infection.

Authors:  Rebecca Scherzer; Michelle Estrella; Yongmei Li; Andy I Choi; Steven G Deeks; Carl Grunfeld; Michael G Shlipak
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

2.  Longitudinal Assessment of Proximal Tubular Dysfunction in HIV Seropositive and Seronegative Persons: Correlates and Implications.

Authors:  Kerry M Sheets; Mohamed G Atta; Derek M Fine; Katie Zook; Allison M Mcfall; Michelle M Estrella; George J Schwartz; Gregory M Lucas
Journal:  J Acquir Immune Defic Syndr       Date:  2017-05-01       Impact factor: 3.731

Review 3.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

Review 4.  HIV therapies and the kidney: some good, some not so good?

Authors:  Lene Ryom; Amanda Mocroft; Jens Lundgren
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

5.  Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.

Authors:  Vasantha Jotwani; Rebecca Scherzer; David V Glidden; Megha Mehrotra; Patricia Defechereux; Albert Liu; Monica Gandhi; Michael Bennett; Steven G Coca; Chirag R Parikh; Robert M Grant; Michael G Shlipak
Journal:  J Acquir Immune Defic Syndr       Date:  2018-06-01       Impact factor: 3.731

6.  Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.

Authors:  Lene Ryom; Amanda Mocroft; Ole Kirk; Signe W Worm; David A Kamara; Peter Reiss; Michael Ross; Christoph A Fux; Philippe Morlat; Olivier Moranne; Colette Smith; Jens D Lundgren
Journal:  J Infect Dis       Date:  2013-02-04       Impact factor: 5.226

7.  Tenofovir use and urinary biomarkers among HIV-infected women in the Women's Interagency HIV Study (WIHS).

Authors:  Ikwo Oboho; Alison G Abraham; Lorie Benning; Kathryn Anastos; Anjali Sharma; Mary Young; Pamela Burian; Monica Gandhi; Mardge Cohen; Lynda Szczech
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-01       Impact factor: 3.731

8.  Sepsis as a major determinant of outcome in critically ill HIV/AIDS patients: don't forget acute kidney injury.

Authors:  José António Lopes; Sofia Jorge
Journal:  Crit Care       Date:  2012-12-10       Impact factor: 9.097

9.  Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection.

Authors:  Murli Purswani; Kunjal Patel; Jeffrey B Kopp; George R Seage; Miriam C Chernoff; Rohan Hazra; George K Siberry; Lynne M Mofenson; Gwendolyn B Scott; Russell B Van Dyke
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

10.  Tenofovir disoproxil fumarate initiation and changes in urinary biomarker concentrations among HIV-infected men and women.

Authors:  William R Zhang; Rebecca Scherzer; Michelle M Estrella; Simon B Ascher; Anthony Muiru; Vasantha Jotwani; Carl Grunfeld; Chirag R Parikh; Deborah Gustafson; Seble Kassaye; Anjali Sharma; Mardge Cohen; Phyllis C Tien; Derek K Ng; Frank J Palella; Mallory D Witt; Ken Ho; Michael G Shlipak
Journal:  AIDS       Date:  2019-03-15       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.